Pfizer has promoted Albert Bourla, seen as a likely successor to ... Bourla is a doctor of veterinary medicine and has a PhD in biology of reproduction from the Veterinary School of Aristotle ...

Pfizer CEO is set to meet with activist investor Starboard Value after the investor acquired a $1 billion stake in the ...

CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Albert Bourla could be seen saying: "We know that the two doses of the vaccine offer very limited protection, if any." Jerome tweeted: "If this video is legit, it has to sound off some alarms ...

Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing Albert Bourla talks about his employees' effort to develop a COVID-19 vaccine in record ...

DAVOS, Switzerland—Albert Bourla has ambitious plans to turn around the situation at Pfizer. The market will decide if talk is cheap, but at least for now the stock looks cheap, or so the ...

Pfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January by chief operating officer Albert Bourla. In contrast to Merck & Co. which has rescinded a company ...

These dogs may not be man’s best friend. A UK veterinarian who works with all types of dogs has revealed which breeds he would avoid owning, citing their common health issues that can be costly ...

“Albert Bourla is very proud of his Greek heritage and of his Jewish heritage, from Thessaloniki,” the Israeli prime minister said. (JTA) — Israel’s government has signed an agreement with ...

In addition to meeting your pet’s primary care needs, such as supplying food, water and a safe place to live, it’s essential to keep your pet healthy with regular veterinarian visits.

Pfizer’s chief executive, Dr. Albert Bourla, said the drug-making company is in a “very advanced stage” and should know by the end of October whether the coronavirus vaccine they are ...

Albert Bourla said Pfizer expects to price its treatment, called Paxlovid, close to where rival Merck & Co Inc has priced its oral antiviral drug candidate. The companies said the vaccine ...